A30.2
Borderline tuberculoid leprosy
Clinical Classification Guidelines
Inclusion Terms
- BT leprosy
Medical Intelligence & Overview
Borderline tuberculoid leprosy, classified under ICD-10 code A30.2, is a form of leprosy that lies between tuberculoid leprosy (more localized and less contagious) and lepromatous leprosy (more widespread and contagious). It is part of the spectrum of leprosy, a chronic infectious disease caused by the bacterium Mycobacterium leprae. This intermediate form exhibits features of both ends of the spectrum, making its presentation and management somewhat unique. Recognized as BT leprosy, this condition requires attentive diagnosis and treatment to prevent transmission and complications.
Causes & Symptoms
Clinical Causes: Prolonged contact with an individual infected with leprosy Close physical contact over extended periods Poor immune response or compromised immune system Living in areas with high endemic rates of leprosy Genetic predisposition in some individuals
Key Symptoms: Localized skin lesions that are slightly raised or flat Lesions often have well-defined edges and may be hypopigmented or erythematous Nerve involvement leading to numbness or tingling in affected regions Muscle weakness in some cases Loss of sensation in the skin over the lesions Possible minor ulcerations or skin breakdown in places with nerve damage Lymphadenopathy (enlarged lymph nodes) near affected areas
Diagnostic & Treatment
Diagnosis Path: Detailed patient history focusing on contact exposure Physical examination of skin lesions and neurological assessment Skin smears to detect acid-fast bacilli (though often scant or absent) Skin biopsy revealing granulomatous inflammation with characteristic lymphocytes and occasional bacilli Laboratory tests to exclude other skin or neurological conditions Assessment of nerve function to evaluate nerve involvement
Treatment Protocols: A combination of antibiotics such as dapsone, rifampicin, and clofazimine Treatment duration commonly ranges from 6 to 12 months, adjusted based on response Monitoring for adverse drug reactions and nerve function improvements Regular follow-up to assess treatment efficacy and detect relapses Supportive care for nerve-related symptoms, including physiotherapy Patient education on disease transmission, hygiene, and avoiding stigma
Clinical Advice & FAQs
Billing Guidance
Is A30.2 a billable ICD-10 code?
Yes, A30.2 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report A30.2?
Clinical documentation must specify the nature of Borderline tuberculoid leprosy and any associated comorbidities for accurate reporting.
Cite this Clinical Reference